User:Fu Hung Shiu/sandbox

Thota Ganesh(born May 10, 1970) is an Indian-American scientist who has made considerable contributions to the field of organic chemistry and Medicinal chemistry. He serves as associate professor in the School of Medicine at Emory University, Atlanta GA.

Education
Ganesh grew up in Anantasagar, a village in Telangana, India. He attended obtained Bachler degree in Osmania University, and also got his Master's degree (1994) and Ph.D (1999) in organic chemistry at the same institute. He obtained postdoc training at IIT-Bombay, Durham University (UK), and Virginia Tech (USA) before moving to Emory University (USA)

Career
Ganesh is an associate professor in the Department of Pharmacology at Emory University. He served in several national and international scientific committees including National Institutes of Health (NIH) grant review committees and served on the scientific review board of ADDF. He co-founded (along with Raymond J. Dingledine and Dennis McNamara) a small pharma company called Pyrefin Inc., in 2019, which develops novel anti-inflammatory drugs to treat memory and cognitive deficits in Epilepsy and other neurodgenerative diseases such as Alzheimer’s disease. He serves on board of Pyrefin, Inc

Research and work
His early research focused on the modulation of glutamate receptor-mediated synaptic transmission. During this period he and his team discovered that glycine is a coagonist rather than modulator of NMDA receptors, that shrinkage of extracellular space mediates the transition between interictal and ictal states in the high potassium model of seizures, that a single amino acid residue controls calcium permeation in glutamate receptor channels, and that ifenprodil analogs inhibit NMDA receptors by increasing the sensitivity of receptors to proton inhibition. His current research focuses on the myriad roles of neuroinflammation in neurologic disorders. He demonstrated a profound role for EP2 receptor activation by prostaglandin E2 in COX-2 related pathologies. His work highlights the importance of neuroinflammation in epilepsy.

Awards and honors
Dingledine was elected to the US National Academy of Medicine in 2010, the Norwegian Academy of Science and Letters in 2018, and the National Academy of Inventors in 2022. He was elected as a Fellow of American Association for Advancement of Science in 2003, and a Fellow of the American Society for Pharmacology and Experimental Therapeutics in 2020. His early career was profiled in Nature Medicine in 2002. He received the Bristol-Myers Squibb Neuroscience Award in 1989 and again in 1993, the epilepsy basic research award from the American Epilepsy Society in 1995, a Javits Neuroscience Award from the National Institute of Neurological Disorders and Stroke in 1998, the PhRMA Foundation Career Award in Excellence in 1999, and the Robert R Ruffolo Career Achievement Award from the American Society of Pharmacology and Experimental Therapeutics in 2018. Two endowed prizes have been established in his name, the Ray Dingledine Award for Extraordinary Graduate Achievement in 2018 and the Ray Dingledine Research Impact Award in Pharmacology & Chemical Biology (2019). In 2023, he is awarded the inaugural AMSPC Award in Pharmacology Research and Administration from the Association of Medical School Pharmacology Chairs (AMSPC).

Personal life
Dingledine has two sons, Brian and Roger. Dingledine has grown bonsai trees since 1971 and for many years was an avid swimmer with a local Master’s group. He competed in the relay division of the Tugaloo Triathlon and his team (3 Stooges) took first place in 2001, 2003 and 2005, thereby serving as Georgia state champions.